The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000697381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/05/2026
Date registered
Help: Date registered
11/06/2026
Date last updated
Help: Date last updated
11/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
REMDAS-A2: Recollection of Event Memory following Drugs, Alcohol, and Stress
Scientific title
REMDAS-A2: Recollection of Event Memory following Drugs, Alcohol, and Stress in Adults Who Have Used Substances Previously
Additional trial identifiers [1] 316816 0
nil
Universal Trial Number (UTN)
Trial acronym
REMDAS-A2
Related trial records

Health condition
Health condition(s) studied:
Memory Impairment 341189 0
Condition category
Condition code
Mental Health 337274 337274 0 0
Studies of normal psychology, cognitive function and behaviour

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This trial uses a parallel-group between-subjects design where each participant will attend 1 session. Participants will be randomised to receive one of four conditions. Comparison will be made between alcohol (positive control, to an approximate blood alcohol concentration [BAC] of 0.08% at 1 hour; beverage volume is individually calculated based on participant body weight and biological sex using the Widmark Formula, a standard BAC pharmacokinetic formula) and placebo (negative control) with the substance of interest dexamfetamine (20mg oral tablet), and their combination (polysubstance condition), across four arms:

Arm 1: dexamfetamine tablets (20mg) + placebo drink
Arm 2: placebo tablets + alcohol drink (variable volume; ~0.08% BAC)
Arm 3: dexamfetamine tablets (20mg) + alcohol drink (variable volume; ~0.08% BAC)
Arm 4: placebo tablets + placebo drink

The study uses a randomised double-blind, double-dummy design. Participants will consume two substances (drinks and tablets) but will not know which is placebo and which is active. The tablets are consumed, with the drink consumed immediately after, over a 10-15 minute period.

Participants will be instructed to abstain from alcohol and drugs for 24 hours, and from cigarettes, caffeine, and eating for two hours before the session. At the beginning of the session, participants will screen for recent substance use and pregnancy, complete the demographics and drug history questionnaire, and receive a baseline blood (via venepuncture) and saliva test. Dexamfetamine/placebo pills will be administered by the study research nurse. Blood samples will be taken across a total of 2 time points to quantify plasma levels of substances.

The stress and memory tests will occur at the study visit. The stress test is the Maastricht Acute Stress Test (MAST), which involves arm submersion in ice water alongside a social threat (maths task while evaluated and filmed). Memory will be tested via recall of the MAST event (to-be-remembered items counterbalanced across arms), the DRM word list task, and a face recognition task (employing the Chicago Face database). Memory and stress tests will occur approximately 30 minutes post substance administration. Salivary cortisol will be collected to quantify stress levels. These tasks will be completed by trained researchers.

Participants will remain on site until it is safe for them to leave as per standard clinical protocols (e.g., >4 hours since dose, clinician review).
Intervention code [1] 333528 0
Treatment: Other
Description of the comparator or control
Positive control: Alcohol; Vodka (40% Alcohol by Volume; ABV) mixed with tonic water at a 1:3 ratio, titrated to achieve a target blood alcohol concentration (BAC) of 0.08%, served in an cup with the rim sprayed with vodka (40% ABV). Placebo beverage: tonic water (volume matched to the individually calculated alcohol drink volume for each participant), served in an identical cup with the rim sprayed with vodka (40% ABV) to simulate the sensory cues of alcohol consumption.

Negative control: placebo tablets designed to look the same as the dexamphetamine tablets. Placebo formulation includes: Microcrystalline Cellulose, Colloidal Silicon Dioxide, Sodium Starch Glycolate, Sodium Stearyl Fumarate.

Consumption is monitored by the research nurse to ensure adherence and safety
Control group
Placebo

Outcomes
Primary outcome [1] 344803 0
Recall memory under stress
Timepoint [1] 344803 0
Approx 45 mins post substance ingestion
Primary outcome [2] 344864 0
Recall memory
Timepoint [2] 344864 0
Approx 45 mins post substance ingestion
Primary outcome [3] 344865 0
Face recognition memory (visual)
Timepoint [3] 344865 0
Approx 45 mins post substance ingestion
Secondary outcome [1] 459344 0
Salivary cortisol
Timepoint [1] 459344 0
Three time points within the session: baseline, 35 minutes post-stressor, and 50 minutes post-stressor.
Secondary outcome [2] 459550 0
Stress ratings
Timepoint [2] 459550 0
Assessed 6 times across session; 1 baseline, 1 approx 45 mins post MAST, 15 mins later, 15 mins later again, approx 3 hours later, and at discharge
Secondary outcome [3] 459551 0
Positive and Negative Affect Schedule (PANAS)
Timepoint [3] 459551 0
Collected at baseline and approx 45 mins post stressor (MAST)
Secondary outcome [4] 459552 0
Amphetamine intoxication
Timepoint [4] 459552 0
6 time points: 45 mins post drug administration, 15 mins after that, 15 mins after that, Then at approx 4 hours post drug administration) and at discharge (approx 5 hours).
Secondary outcome [5] 459553 0
Alcohol intoxication
Timepoint [5] 459553 0
6 time points: 45 mins post drug administration, 15 mins after that, 15 mins after that, Then at approx 4 hours post drug administration) and at discharge (approx 5 hours).
Secondary outcome [6] 459554 0
Stress and pain responses to MAST: composite
Timepoint [6] 459554 0
Approx 45 mins post stressor
Secondary outcome [7] 459555 0
Stress via salivary alpha amylase
Timepoint [7] 459555 0
Approx 2 mins post stressor
Secondary outcome [8] 462436 0
Recall memory
Timepoint [8] 462436 0
Approx 2 hours post substance ingestion

Eligibility
Key inclusion criteria
1) Self-reported previous experience with the substance of interest but not current regular use. Regular use is defined as taking amphetamines for non-medical purposes more than once a week.
2) Adequate cognition and English to consent and complete the study. This will be determined by the researcher who administers the phone screening.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Current, clinically significant physical disease (e.g., cardiac, liver). The nurse or doctor associated with the study will make this determination based on an examination of the potential participant.
2) Severe psychiatric illness (i.e., schizophrenia, suicide risk). The nurse or doctor associated with the study will make this determination based on an examination of the potential participant.
3) Current substance use disorder other than nicotine. The nurse or doctor associated with the study will make this determination based on an examination of the potential participant and the diagnostic tools.
4) Previous hypersensitivity/adverse reaction to the studied drugs. We will evaluate this based on the potential participant’s self-report.
5) Current medication use that is a contraindication for the study drug or interferes with drug absorption. The nurse or doctor associated with the study will make this determination based on an examination of the potential participant. Stable antidepressant use for > one month will be permitted.
6) Oral-contraceptive use in females. We will evaluate this based on the potential participant’s self-report.
7) Current pregnancy/lactation. We will evaluate this based on the potential participant’s self-report in the first instance (phone screen) but also via pregnancy testing prior to study session commencement.
8) Women of child-bearing capacity who are not prepared to use (non-pharmacological) contraception during the study. We will evaluate this based on the potential participant’s self-report.
9) Participation in at least 1 session of the REMDAS-A study (See ANZCTR: ACTRN12624000645550) due to priming and familiarity with study activities.

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis
Data analyses will be conducted using SPSS, Jamovi, and R. The primary analysis will be a Bayesian independent samples t-test comparing the polysubstance condition (dexamfetamine + alcohol) to the double placebo on memory outcomes. Secondary analyses will employ Bayesian one-way between-subjects ANOVAs to assess main effects across all four conditions, with planned contrasts comparing each active arm to placebo. An exploratory aim will examine whether acute stress moderates substance effects on memory.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29287 0
Royal North Shore Hospital - St Leonards
Recruitment postcode(s) [1] 45606 0
2065 - St Leonards

Funding & Sponsors
Funding source category [1] 321410 0
Government body
Name [1] 321410 0
Australian Research Council (ARC)
Country [1] 321410 0
Australia
Funding source category [2] 321435 0
Other
Name [2] 321435 0
Ramsay Health Care
Country [2] 321435 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 324177 0
None
Name [1] 324177 0
Address [1] 324177 0
Country [1] 324177 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319949 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 319949 0
Ethics committee country [1] 319949 0
Australia
Date submitted for ethics approval [1] 319949 0
16/12/2025
Approval date [1] 319949 0
04/03/2026
Ethics approval number [1] 319949 0
2025/ETH02895

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148926 0
Dr Lauren Monds
Address 148926 0
Central Clinical School, Faculty of Medicine and Health, USYD; 92 Parramatta Rd, Camperdown, NSW, 2050
Country 148926 0
Australia
Phone 148926 0
+61 2 9036 3136
Fax 148926 0
Email 148926 0
Contact person for public queries
Name 148927 0
Dr. Lauren Monds
Address 148927 0
Central Clinical School, Faculty of Medicine and Health, USYD; 92 Parramatta Rd, Camperdown, NSW, 2050
Country 148927 0
Australia
Phone 148927 0
+61 2 9036 3136
Fax 148927 0
Email 148927 0
Contact person for scientific queries
Name 148928 0
Dr. Lauren Monds
Address 148928 0
Central Clinical School, Faculty of Medicine and Health, USYD; 92 Parramatta Rd, Camperdown, NSW, 2050
Country 148928 0
Australia
Phone 148928 0
+61 2 9036 3136
Fax 148928 0
Email 148928 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.